Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 14 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding Oruka Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 23 | 1 | 21 | −1 |
| Shares | 2.83M | 32.5K | 3.26M | +459.6K (+16.4%) |
| Value | $5.75M | $65.9K | $6.55M | +$867.5K (+15.3%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (3)
Institutions that held Oruka Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 125 | $251 | 0.00% |
| Qube Research & Technologies Ltd | 50 | $101 | 0.00% |
| JPMorgan Chase & Co | 12 | $24 | 0.00% |
Sold out (4)
Institutions that held Oruka Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Murchinson Ltd. | 50,593 | $102.7K |
| Citadel Advisors LLC | 1,541 | $3.13K |
| TD Waterhouse Canada Inc. | 1,300 | $2.63K |
| The PNC Financial Services Group, Inc. | 500 | $1.01K |
Not filed for Q3 2023 yet (1)
Institutions that held Oruka Therapeutics, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Tekla Capital Management LLC | 32,461 | $65.9K |